The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study
Open accessAbstract
PURPOSE: To compare the survival outcomes of neoadjuvant three-dimensional conformal radiotherapy (RT) followed by hepatectomy with hepatectomy alone in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). PATIENTS AND METHODS: A randomized, multicenter controlled study was conducted from January 2016 to December 2017 in patients with resectable HCC and PVTT. Patients were randomly assigned to receive neoadjuvant RT followed by hepatectomy (n = 82) or hepatectomy alone (n = 82). The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines were used to evaluate the therapeutic effects of RT. The primary end point was overall survival. The expression of interleukin-6 (IL-6) in patients’ serum before RT and in surgical specimens was correlated with response to RT. RESULTS: In the neoadjuvant RT group, 17 patients (20.7%) had partial remission. The overall survival rates for the neoadjuvant RT group at 6, 12, 18, and 24 months were 89.0%, 75.2%, 43.9%, and 27.4%, respectively, compared with 81.7%, 43.1%, 16.7%, and 9.4% in the surgery-alone group ( P < .001). The corresponding disease-free survival rates were 56.9%, 33.0%, 20.3%, and 13.3% versus 42.1%, 14.9%, 5.0%, and 3.3% ( P < .001). On multivariable Cox regression analyses, neoadjuvant RT significantly reduced HCC-related mortality and HCC recurrence rates compared with surgery alone (hazard ratios, 0.35 [95% CI, 0.23 to 0.54; P < .001] and 0.45 [95% CI, 0.31 to 0.64; P < .001]). Increased expressions of IL-6 in pre-RT serum and tumor tissues were significantly associated with resistance to RT. CONCLUSION: For patients with resectable HCC and PVTT, neoadjuvant RT provided significantly better postoperative survival outcomes than surgery alone. IL-6 may predict response to RT in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, Y., Zhang, F., Tsai, Y., Yang, X., Li, Y., Duan, S., Wang, X., Keng, P., & Lee, S. O. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0534-1 · Cited by 84
RetractedDindo, D., Demartines, N., & Clavien, P.-A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133083.54934.ae · Cited by 31,378
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Interleukin-6 signaling pathway in targeted therapy for cancer
Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 686
Torzilli, G., Belghiti, J., Kokudo, N., Takayama, T., Capussotti, L., Nuzzo, G., Vauthey, J.-N., Choti, M. A., De Santibanes, E., Donadon, M., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31828329b8 · Cited by 496
Kokudo, T., Hasegawa, K., Matsuyama, Y., Takayama, T., Izumi, N., Kadoya, M., Kudo, M., Ku, Y., Sakamoto, M., Nakashima, O., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.044 · Cited by 491
(2012) · Hepatogastroenterology · doi:10.5754/hge12157 · Cited by 460
Yoon, S. M., Ryoo, B.-Y., Lee, S. J., Kim, J. H., Shin, J. H., An, J. H., Lee, H. C., & Lim, Y.-S. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5847 · Cited by 446
Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Shi, J., Lai, E. C. H., Li, N., Guo, W.-X., Xue, J., Lau, W. Y., Wu, M.-C., & Cheng, S.-Q. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0940-4 · Cited by 287
Self-citationUtsunomiya, T., Shimada, M., Kudo, M., et al. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000821 · Cited by 165
Peng, Z., Guo, R., Zhang, Y., Lin, X., Chen, M., & Lau, W. Y. (2012) · Cancer · doi:10.1002/cncr.26561 · Cited by 159
Self-citationSalvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma
Lau, W. Y., Ho, S. K. W., Yu, S. C. H., Lai, E. C. H., Liew, C.-T., & Leung, T. W. T. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133123.11932.19 · Cited by 146
Self-citationThe role of IL-6 in the radiation response of prostate cancer
Wu, C., Chen, M., Chen, W., & Hsieh, C. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-159 · Cited by 144
Lau, W. Y., & Lai, E. C. H. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9549-7 · Cited by 143
Self-citationShui, Y., Yu, W., Ren, X., Guo, Y., Xu, J., Ma, T., Zhang, B., Wu, J., Li, Q., Hu, Q., et al. (2018) · Radiation Oncology · doi:10.1186/s13014-018-1136-5 · Cited by 97
Yang, T., Lin, C., Zhai, J., Shi, S., Zhu, M., Zhu, N., Lu, J., Yang, G.-S., & Wu, M. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1188-0 · Cited by 86
Ng, J., & Wu, J. J. (2012) · Hepatitis Monthly · doi:10.5812/hepatmon.7635 · Cited by 78
DNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of Radioresistance
Centurione, L., & Aiello, F. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00175 · Cited by 75
Shuqun, C., Minshan, C., & Cai, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12817 · Cited by 70
Li, N., Feng, S., Xue, J., Wei, X., Shi, J., Guo, W., Lau, W. Y., Wu, M., Cheng, S., & Meng, Y. (2016) · HPB · doi:10.1016/j.hpb.2016.04.003 · Cited by 61
Self-citationCilia loss sensitizes cells to transformation by activating the mevalonate pathway
Deng, Y.-Z., Cai, Z., Shi, S., Jiang, H., Shang, Y., Ma, N., Wang, J. J., Guan, D., Chen, T.-W., Rong, Y., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20170399 · Cited by 56
Self-citationLiang, L., Chen, T., Li, C., Xing, H., Han, J. S., Wang, M.-D., Zhang, H., Lau, W. Y., Wu, M., Shen, F., et al. (2018) · HPB · doi:10.1016/j.hpb.2018.06.1804 · Cited by 47
Self-citationRole of Interleukin-6 in the Radiation Response of Liver Tumors
Chen, M., Hsieh, C., Chen, W., & Lai, C. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.07.2360 · Cited by 35
Furukawa, K., Shiba, H., Horiuchi, T., Shirai, Y., Haruki, K., Fujiwara, Y., Sakamoto, T., Gocho, T., & Yanaga, K. K. (2017) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.436 · Cited by 28
Lin, H., Li, X., Liu, Y., & Hu, Y. (2018) · ANZ Journal of Surgery · doi:10.1111/ans.14387 · Cited by 21
Cha, H., Lee, E., & Seong, J. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i11.2077 · Cited by 15
Systemic management for patients with hepatobiliary tumors in a multi-dimensional view
Lin, J., & Zhao, H. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.07.21 · Cited by 8
Cited by
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Self-citationManagement of Hepatocellular Carcinoma: A Review
Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2022.7989 · Cited by 763
Xie, D.-Y., Ren, Z.-G., Zhou, J., Fan, J., & Gao, Q. (2020) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-20-480 · Cited by 479
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Self-citation2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Metadata
- Authors
- Wei, X., Jiang, Y., Zhang, X., Feng, S., Zhou, B., Ye, X., Xing, H., Xu, Y., Shi, J., Guo, W., Zhou, D., Zhang, H., Sun, H., Huang, C., Lu, C., Zheng, Y., Meng, Y., Huang, B., Cong, W., Lau, W. Y., & Cheng, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-08-20
- Volume
- 37
- Issue
- 24
- Pages
- 2141-2151
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2958829328
- Cited by
- 285
- References
- 30
- FWCI
- 16.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.